Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | MC5R | P33032 | 1/20 | 0.44 |
| ▸ | MC1R | Q01726 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 3/20 | 0.44 |
| ▸ | METAP1 | P53582 | 3/20 | 0.44 |
| ▸ | ACP3 | P15309 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1520324 | 0.83 | HPGD (0.59) | CYP2C19HPGDCYP2C9HTTALDH1A1 | |
| SCHEMBL5720984 | 0.83 | HPGD (0.59) | CYP2C19HPGDCYP2C9HTTALDH1A1 | |
| SCHEMBL29666532 | 0.83 | HPGD (0.59) | CYP2C19HPGDCYP2C9HTTALDH1A1 | |
| SCHEMBL16541031 | 0.83 | HPGD (0.59) | CYP2C19HPGDCYP2C9HTTALDH1A1 | |
| SCHEMBL6503232 | 0.82 | CYP2C19 (0.50) | CYP2C19HPGDCYP2C9HTTALDH1A1 | |
| SCHEMBL250818 | 0.81 | CYP2C19 (0.49) | CYP2C19HPGDCYP2C9HTTALDH1A1 | |
| SCHEMBL27222140 | 0.80 | CYP2C19 (0.47) | CYP2C19HPGDCYP2C9HTTALDH1A1 | |
| SCHEMBL4195634 | 0.80 | CYP2C19 (0.47) | CYP2C19HPGDCYP2C9HTTALDH1A1 | |
| Oxalic Acid SCHEMBL17065865 | 0.79 | ALDH1A1 (0.48) | CYP2C19HPGDCYP2C9HTTALDH1A1 | |
| SCHEMBL27346979 | 0.78 | CYP2C19 (0.47) | CYP2C19HPGDCYP2C9HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020023502-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20140050694-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-20 | — | — | US | disclosed |
| US-20100092578-A1 | PROTEIN KINASE C IOTA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-15 | — | — | US | disclosed |
| US-7642400-B2 | Transgenic animals, inhibitors of PKC iota signaling, methods for inhibiting PKC iota signaling, identifying inhibitors of PKC iota signaling, and methods for diagnosing cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
| WO-2008156654-A2 | CYTOSKELETON MODULATORS FOR TREATING METABOLIC DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20070283451-A1 | Protein Kinase C Iota | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-12-06 | — | — | US | disclosed |
| US-6787125-B1 | DISPENSING NEMATODE WORMS INTO MULTI-WELL PLATE CONTAINING CARBOXYMETHYL CELLULOSE; CONTACTING WITH CHEMICAL; DETECTING A SIGNAL INDICATING CHANGES; DRUG SCREENING; HIGH THROUGHPUT ASSAY | DEVGEN NV (BE) | 2004-09-07 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | CYP2C19 2872/4885HPGD 503/4885CYP2C9 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.